{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:12:38Z","timestamp":1791839558397,"version":"4.3.4"},"reference-count":58,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Deutsche Derma Gesell"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Used since 2011 in the USA and 2012 in the EU, Janus kinase inhibitors (JAKi) are gaining increasing acceptance as a treatment for dermatological diseases such as atopic dermatitis, psoriasis, psoriatic arthritis, alopecia areata, chronic hand eczema and vitiligo. Knowledge of their mechanism of action and potential side effects is necessary for a safe and effective use. Their short half\u2010life requires daily administration, enables good controllability and is appreciated by many patients due to the rapid onset of action and the absence of subcutaneous or intravenous injections.<\/jats:p><jats:p>Common side effects are upper respiratory tract infections as well as varicella zoster virus reactivations. Serious infections can occur in rare cases, which may take a problematic course. An increased risk of cardiovascular events has been described in certain JAKi, so alternative treatment should be preferred in patients at cardiovascular risk. In studies on rheumatoid arthritis, an increased incidence of malignancies (bronchial carcinoma, lymphoma) was observed with tofacitinib. JAKi have also been associated with more aggressive progression of epithelial skin tumors. Animal studies indicate teratogenic effects during pregnancy. Older patients and those at increased risk should only receive JAKi after careful risk\u2010benefit assessment. Appropriate preliminary examinations and regular laboratory monitoring are necessary to ensure safe therapy.<\/jats:p>","DOI":"10.1111\/ddg.15796","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T13:48:38Z","timestamp":1757944118000},"page":"1127-1140","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Adverse effects of Janus kinase inhibitors with relevance for daily practice in dermatology"],"prefix":"10.1111","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0135-9643","authenticated-orcid":false,"given":"Anika","family":"Rajput Khokhar","sequence":"first","affiliation":[{"name":"Department of Dermatology Venereology and Allergology Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin corporate member of Freie Universit\u00e4t Berlin and Humboldt\u2010Universit\u00e4t zu Berlin  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamran","family":"Ghoreschi","sequence":"additional","affiliation":[{"name":"Department of Dermatology Venereology and Allergology Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin corporate member of Freie Universit\u00e4t Berlin and Humboldt\u2010Universit\u00e4t zu Berlin  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2357-4184","authenticated-orcid":false,"given":"Julia","family":"Huynh","sequence":"additional","affiliation":[{"name":"Department of Dermatology Venereology and Allergology Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin corporate member of Freie Universit\u00e4t Berlin and Humboldt\u2010Universit\u00e4t zu Berlin  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,9,15]]},"reference":[{"issue":"3","key":"e_1_2_14_2_1","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00281-019-00742-7","article-title":"T cell pathology in skin inflammation","volume":"41","author":"Sabat R","year":"2019","journal-title":"Semin Immunopathol"},{"issue":"11","key":"e_1_2_14_3_1","first-page":"1485","article-title":"Pharmacology of inhibitors of Janus kinases \u2013 Part 1: Pharmacokinetics","volume":"20","author":"Eichner A","year":"2022","journal-title":"J Dtsch Dermatol Ges"},{"issue":"1","key":"e_1_2_14_4_1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/ddg.14668","article-title":"JAK\u2010inhibitors in dermatology \u2013 small molecules, big impact? Overview of the mechanism of action, previous study results and potential adverse effects","volume":"20","author":"Klein B","year":"2022","journal-title":"J Dtsch Dermatol Ges"},{"issue":"4","key":"e_1_2_14_5_1","doi-asserted-by":"crossref","DOI":"10.1111\/exd.15080","article-title":"TYK2 inhibition with deucravacitinib ameliorates erosive oral lichen planus","volume":"33","author":"Stolte KN","year":"2024","journal-title":"Exp Dermatol"},{"issue":"10451","key":"e_1_2_14_6_1","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0140-6736(24)01027-4","article-title":"Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double\u2010blind, phase 3 trials","volume":"404","author":"Bissonnette R","year":"2024","journal-title":"Lancet"},{"key":"e_1_2_14_7_1","doi-asserted-by":"crossref","first-page":"293","DOI":"10.5414\/ALX02272E","article-title":"Janus kinase inhibitors for the therapy of atopic dermatitis","volume":"5","author":"Traidl S","year":"2021","journal-title":"Allergol Select"},{"issue":"1","key":"e_1_2_14_8_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41927-023-00370-7","article-title":"Clinician and patient views on janus kinase inhibitors in the treatment of inflammatory arthritis: a mixed methods study","volume":"8","author":"Souza S","year":"2024","journal-title":"BMC Rheumatol"},{"issue":"7","key":"e_1_2_14_9_1","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","article-title":"Modulation of innate and adaptive immune responses by tofacitinib (CP\u2010690,550)","volume":"186","author":"Ghoreschi K","year":"2011","journal-title":"J Immunol"},{"issue":"12","key":"e_1_2_14_10_1","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1001\/jamadermatol.2023.3830","article-title":"Janus Kinase Inhibitors and Adverse Events of Acne: A Systematic Review and Meta\u2010Analysis","volume":"159","author":"Martinez J","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"3","key":"e_1_2_14_11_1","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s13555-023-00892-5","article-title":"A Review on the Safety of Using JAK Inhibitors in Dermatology: Clinical and Laboratory Monitoring","volume":"13","author":"Samuel C","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"9","key":"e_1_2_14_12_1","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/ddg.15452","article-title":"Upadacitinib induced erythema, papules and pustules \u2010 Is it really acne or is it rosacea?","volume":"22","author":"H\u00f6lzle I","year":"2024","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_14_13_1","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v103.11657","article-title":"Acneiform Lesions but not Acne after Treatment with Janus Kinase Inhibitors: Diagnosis and Management of Janus Kinase\u2010acne","volume":"103","author":"Ballanger F","year":"2023","journal-title":"Acta Derm Venereol"},{"issue":"9","key":"e_1_2_14_14_1","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15688","article-title":"Management of acne induced by JAK inhibitors","volume":"35","author":"Correia C","year":"2022","journal-title":"Dermatol Ther"},{"issue":"5","key":"e_1_2_14_15_1","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41584-022-00767-7","article-title":"Oral surveillance and JAK inhibitor safety: the theory of relativity","volume":"18","author":"Winthrop KL","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"10290","key":"e_1_2_14_16_1","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","article-title":"Once\u2010daily upadacitinib versus placebo in adolescents and adults with moderate\u2010to\u2010severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double\u2010blind, randomised controlled phase 3 trials","volume":"397","author":"Guttman\u2010Yassky E","year":"2021","journal-title":"Lancet"},{"issue":"10290","key":"e_1_2_14_17_1","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/S0140-6736(21)00589-4","article-title":"Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate\u2010to\u2010severe atopic dermatitis (AD Up): results from a randomised, double\u2010blind, placebo\u2010controlled, phase 3 trial","volume":"397","author":"Reich K","year":"2021","journal-title":"Lancet"},{"issue":"10246","key":"e_1_2_14_18_1","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","article-title":"Efficacy and safety of abrocitinib in adults and adolescents with moderate\u2010to\u2010severe atopic dermatitis (JADE MONO\u20101): a multicentre, double\u2010blind, randomised, placebo\u2010controlled, phase 3 trial","volume":"396","author":"Simpson EL","year":"2020","journal-title":"Lancet"},{"key":"e_1_2_14_19_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.152120","article-title":"Opportunistic infections associated with Janus kinase inhibitor treatment for rheumatoid arthritis: A structured literature review","volume":"58","author":"Winthrop K","year":"2023","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"e_1_2_14_20_1","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s10067-021-06003-z","article-title":"Effect of JAK inhibitors on high\u2010 and low\u2010density lipoprotein in patients with rheumatoid arthritis: a systematic review and network meta\u2010analysis","volume":"41","author":"Li N","year":"2022","journal-title":"Clin Rheumatol"},{"issue":"11","key":"e_1_2_14_21_1","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1001\/jamadermatol.2022.3516","article-title":"Association of Risk of Incident Venous Thromboembolism With Atopic Dermatitis and Treatment With Janus Kinase Inhibitors: A Systematic Review and Meta\u2010analysis","volume":"158","author":"Chen TL","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"2","key":"e_1_2_14_22_1","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/ard-2022-223050","article-title":"Venous thromboembolism with JAK inhibitors and other immune\u2010modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis","volume":"82","author":"Molander V","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"e_1_2_14_23_1","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1002\/stem.1711","article-title":"Critical role of Jak2 in the maintenance and function of adult hematopoietic stem cells","volume":"32","author":"Akada H","year":"2014","journal-title":"Stem Cells"},{"issue":"49","key":"e_1_2_14_24_1","doi-asserted-by":"crossref","first-page":"5662","DOI":"10.1038\/sj.onc.1203925","article-title":"Janus kinases: components of multiple signaling pathways","volume":"19","author":"Rane SG","year":"2000","journal-title":"Oncogene"},{"issue":"4","key":"e_1_2_14_25_1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine RL","year":"2005","journal-title":"Cancer Cell"},{"issue":"3","key":"e_1_2_14_26_1","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001370","article-title":"Changes in selected haematological parameters associated with JAK1\/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib","volume":"6","author":"Kay J","year":"2020","journal-title":"RMD Open"},{"issue":"12","key":"e_1_2_14_27_1","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1038\/s41375-021-01261-x","article-title":"Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study","volume":"35","author":"Cervantes F","year":"2021","journal-title":"Leukemia"},{"issue":"2","key":"e_1_2_14_28_1","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/ard-2023-223850","article-title":"Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story","volume":"83","author":"Bonelli M","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"e_1_2_14_29_1","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib","volume":"80","author":"Traves PG","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"e_1_2_14_30_1","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/hon.2525","article-title":"Rheumatoid arthritis and lymphoma: Incidence, pathogenesis, biology, and outcome","volume":"36","author":"Klein A","year":"2018","journal-title":"Hematol Oncol"},{"issue":"7","key":"e_1_2_14_31_1","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1136\/ard-2022-223715","article-title":"Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance","volume":"82","author":"Kristensen LE","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_14_32_1","volume-title":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (BfArM) P, Europ\u00e4ischen Arzneimittel\u2010Agentur (EMA)","author":"Kalanovic D KD","year":"2021"},{"issue":"2","key":"e_1_2_14_33_1","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-004007","article-title":"Long\u2010term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5\u2010year data from the phase 3, randomised SELECT\u2010COMPARE study","volume":"10","author":"Fleischmann R","year":"2024","journal-title":"RMD Open"},{"issue":"1","key":"e_1_2_14_34_1","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002735","article-title":"Safety profile of upadacitinib over 15 000 patient\u2010years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis","volume":"9","author":"Burmester GR","year":"2023","journal-title":"RMD Open"},{"issue":"6","key":"e_1_2_14_35_1","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.therap.2022.04.005","article-title":"Skin cancers under Janus kinase inhibitors: A World Health Organization drug safety database analysis","volume":"77","author":"Jalles C","year":"2022","journal-title":"Therapie"},{"issue":"3","key":"e_1_2_14_36_1","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jaad.2022.11.043","article-title":"Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part II: Methotrexate, alkylating agents, biologics, and small molecule inhibitors","volume":"88","author":"Kreher MA","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"e_1_2_14_37_1","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s11096-023-01634-5","article-title":"Analysis of the association between Janus kinase inhibitors and malignant skin tumors using the Food and Drug Administration Adverse Event Reporting System","volume":"45","author":"Liu T","year":"2023","journal-title":"Int J Clin Pharm"},{"issue":"2","key":"e_1_2_14_38_1","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1056\/NEJMc2304157","article-title":"Cutaneous Squamous\u2010Cell Carcinoma after Treatment with Ruxolitinib or Belumosudil","volume":"389","author":"Lee GH","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"e_1_2_14_39_1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11864-020-00815-y","article-title":"Janus Kinase Inhibitors and Non\u2010Melanoma Skin Cancer","volume":"22","author":"Greif CS","year":"2021","journal-title":"Curr Treat Options Oncol"},{"issue":"6","key":"e_1_2_14_40_1","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1007\/s10875-023-01483-x","article-title":"JAKs and STATs from a Clinical Perspective: Loss\u2010of\u2010Function Mutations, Gain\u2010of\u2010Function Mutations, and Their Multidimensional Consequences","volume":"43","author":"Ott N","year":"2023","journal-title":"J Clin Immunol"},{"issue":"8","key":"e_1_2_14_41_1","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S2468-1253(23)00158-9","article-title":"Tofacitinib concentrations in plasma and breastmilk of a lactating woman with ulcerative colitis","volume":"8","author":"Julsgaard M","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"8","key":"e_1_2_14_42_1","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/ard-2023-224017","article-title":"Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases: results from the phase 2, randomised, double\u2010blind, placebo\u2010controlled MANTA and MANTA\u2010RAy studies","volume":"82","author":"Reinisch W","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_14_43_1","unstructured":"Rinvoq: EPAR \u2013 Product information.2019. Available from:https:\/\/ec.europa.eu\/health\/documents\/community\u2010register\/2021\/20210122150644\/anx_150644_de.pdf(Last accessed January 3 2025)."},{"key":"e_1_2_14_44_1","unstructured":"Fachinformation Olumiant\u00ae.2023. Available from:https:\/\/www.lilly.com\/at\/assets\/pdf\/fachinformation\/at_olumiant_fachinformation.pdf(Last accessed January 3 2025)."},{"key":"e_1_2_14_45_1","unstructured":"Fachinformation XELJANZ\u00ae 5\/10mg Filmtabletten.2023. Available from:https:\/\/figi.pfizer.de\/sites\/default\/files\/FI\u201016033.pdf(Last accessed January 3 2025)."},{"key":"e_1_2_14_46_1","unstructured":"Fachinformation Cibinqo\u00ae 50\/100\/200mg Filmtabletten.2023. Available from:https:\/\/figi.pfizer.de\/sites\/default\/files\/FI\u201023560.pdf(Last accessed January 3 2025)."},{"key":"e_1_2_14_47_1","unstructured":"AgencyEM.Janus Kinase inhibitors (JAKi) Article\u201020 procedure \u2013 EMA confirms measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders.2023."},{"issue":"4","key":"e_1_2_14_48_1","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis","volume":"386","author":"Ytterberg SR","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"e_1_2_14_49_1","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/ddg.15136_g","article-title":"Handlungsempfehlungen zur Risikominimierung beim Einsatz von Januskinase\u2010Inhibitoren zur Therapie chronisch\u2010entz\u00fcndlicher Hauterkrankungen","volume":"21","author":"Wohlrab J","year":"2023","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_14_50_1","unstructured":"Fachinformation Jakavi\u00ae Tabletten.2022. Available from:https:\/\/www.fachinfo.de\/pdf\/014060(Last accessed January 3 2025)."},{"key":"e_1_2_14_51_1","unstructured":"Jakavi: EPAR \u2010 Product Information.2012. Available from:https:\/\/ec.europa.eu\/health\/documents\/community\u2010register\/2017\/20171201139377\/anx_139377_de.pdf(Last accessed January 3 2025)."},{"key":"e_1_2_14_52_1","unstructured":"Kusuri\u2010no\u2010Shiori Delgocitinib.2022.https:\/\/www.rad\u2010ar.or.jp\/siori\/english\/search\/result?n=43533(Last accessed March 9 2024)."},{"key":"e_1_2_14_53_1","unstructured":"Jyseleca: EPAR \u2010 Product information.2020. Available from:https:\/\/ec.europa.eu\/health\/documents\/community\u2010register\/2020\/20200924148982\/anx_148982_de.pdf(Last accessed January 3 2025)."},{"key":"e_1_2_14_54_1","unstructured":"Fachinformation SOTYKTU\u00ae 6 mg Filmtabletten.2023. Available from:https:\/\/fi.b\u2010ms.de\/SOTYKTU(Last accessed January 3 2025)."},{"key":"e_1_2_14_55_1","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.3389\/fimmu.2019.02847","article-title":"Emerging Topical and Systemic JAK Inhibitors in Dermatology","volume":"10","author":"Solimani F","year":"2019","journal-title":"Front Immunol"},{"key":"e_1_2_14_56_1","unstructured":"Sotyktu: EPAR \u2013 Product information.2023. Available from:https:\/\/www.ema.europa.eu\/de\/documents\/product\u2010information\/sotyktu\u2010epar\u2010product\u2010information_de.pdf(Last accessed January 3 2025)."},{"key":"e_1_2_14_57_1","unstructured":"Fachinformation Litfulo\u00ae 50 mg Hartkapseln.2024. Available from:https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=19915Last (Last accessed January 3 2025)."},{"key":"e_1_2_14_58_1","unstructured":"Anzupgo: EPAR \u2013 Product information.2024. Available from:https:\/\/www.ema.europa.eu\/de\/documents\/product\u2010information\/anzupgo\u2010epar\u2010product\u2010information_de.pdf(Last accessed January 3 2025)."},{"key":"e_1_2_14_59_1","unstructured":"Opzelura: EPAR \u2013 Product information.2023. Available from:https:\/\/www.ema.europa.eu\/de\/documents\/product\u2010information\/opzelura\u2010epar\u2010product\u2010information_de.pdf(Last accessed January 3 2025)."}],"container-title":["JDDG: Journal der Deutschen Dermatologischen Gesellschaft"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ddg.15796","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T13:55:58Z","timestamp":1757944558000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ddg.15796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":58,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1111\/ddg.15796"],"URL":"https:\/\/doi.org\/10.1111\/ddg.15796","archive":["Portico"],"relation":{},"ISSN":["1610-0379","1610-0387"],"issn-type":[{"value":"1610-0379","type":"print"},{"value":"1610-0387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"2024-08-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}